Reinforcing Global Excellence – Mehsana Clinical Facility Undergoes Successful FDA Inspection

  |   lambdanews   |   No comment

We are proud to announce that our state-of-the-art 130 bedded clinical facility at Mehsana, Gujarat (India), has been successfully inspected by USFDA between 27th – 31st August ’18 without any Form 483 observations.

We have an impeccable track record with various international regulatory agencies including EMA, WHO, ANVISA (Brazil), MHRA (UK), TGA (Australia), ANSM (France), AGES (Austria), OGYI (Hungry), Turkey (MoH), Polish Regulatory Authority, TPD (Canada), Thailand (MoH), NPRA (Malaysia) and DCGI. This is an important milestone in the continuing growth and success of our organisation. It also reinforces Lambda’s resolute commitment to operate in full compliance with global regulations and guidelines for good clinical practice (GCP) to maintain the highest quality standards for our global clientele.

Headquartered in Ahmedabad (India), we are a leading full-service CRO. Our global presence includes offices at strategic locations like Mehsana (India), Mumbai (India), Poland (Europe), London (UK) and Toronto (Canada).

Our Service Portfolio

Phase I (First in Man) | Bio-analytical | Bioavailability & Bioequivalence | Late Phase Clinical Trials (Phase II-IV) | Data Services (BSP, CDM) | Medical Writing | Central Laboratory | Biosimilar Assays | Medical Imaging | Pharmacovigilance

No Comments

Post A Comment